Risperidone Related Raynaud’s Phenomenon: An Adolescent Case
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Raynaud’s phenomenon is a recurrent vasospastic condition with reducing in peripheral blood flow due to cold, or emotional stress. White, blue and red discolorations occur during the attacks. Serotonin reuptake inhibitors, psychostimulants, and aripiprazole are reported to be related with Raynaud’s phenomenon. Risperidone is an atypical antipsychotic drug with dopaminergic and serotonergic effects. In children and adolescents, risperidone is used for bipolar disorder, tic disorders, conduct disorder, schizophrenia, symptoms of irritability and self-mutilation. Here we report a case of Raynaud’s phenomenon associated with risperidone in a 12-year-old boy. Raynaud’s phenomenon occurred two weeks after starting risperidone and disappeared after stopping risperidone.
Abstract
Raynaud’s phenomenon is a recurrent vasospastic condition with reducing in peripheral blood flow due to cold, or emotional stress. White, blue and red discolorations occur during the attacks. Serotonin reuptake inhibitors, psychostimulants, and aripiprazole are reported to be related with Raynaud’s phenomenon. Risperidone is an atypical antipsychotic drug with dopaminergic and serotonergic effects. In children and adolescents, risperidone is used for bipolar disorder, tic disorders, conduct disorder, schizophrenia, symptoms of irritability and self-mutilation. Here we report a case of Raynaud’s phenomenon associated with risperidone in a 12-year-old boy. Raynaud’s phenomenon occurred two weeks after starting risperidone and disappeared after stopping risperidone.
참고문헌 (17)
- Conley RR, "Risperidone side effects", J Clin Psychiatry, 61(Suppl 8), pp.20~23 (2000)
- Serkan Güneş, "Risperidone Induced Pisa Syndrome in a Male Adolescent", Clinical Psychopharmacology and Neuroscience, 14(1), pp.104~106 (2016), 대한정신약물학회
- Hosseini SH, "Peripheral edema occurring during treatment with risperidone combined with citalopram", Case Rep Med, 2012, pp.540732~ (2012)
- Leung JY, "Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system", Pharmacol Ther, 135, pp.113~122 (2012)[DOI]
- O'connor CM, "Raynaud's phenomenon", J Vasc Nurs, 19, pp.87~92 (2001)[DOI]
- Zenone T, "Raynaud phenomenon with organic microangiopathy and prolonged treatment with bromocriptine", Rev Med Interne, 17, pp.948~950 (1996)[DOI]
- Rudnick A, "Fluoxetine-induced Raynaud's phenomenon", Biol Psychiatry, 41, pp.1218~1221 (1997)[DOI]
- Peiro AM, "Citalopram-induced Raynaud's phenomenon", Rheumatol Int, 27, pp.599~601 (2007)[DOI]
- Camkurt MA, "Aripiprazole-induced Raynaud's phenomenon: An adolescent case", J Child Adolesc Psychopharmacol, 26, pp.953~954 (2016)[DOI]
- Syed RH, "Methylphenidate and dextroamphetamineinduced peripheral vasculopathy", J Clin Rheumatol, 14, pp.30~33 (2008)[DOI]
- Ratchford EV, "Raynaud's phenomenon", Vasc Med, 20, pp.269~271 (2015)[DOI]
- Garner R, "Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies", BMJ Open, 5, pp.e006389~ (2015)[DOI]
- Gokcen C, "Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl", J Child Adolesc Psychopharmacol, 23, pp.428~430 (2013)[DOI]
- Coleiro B, "Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine", Rheumatology (Oxford), 40, pp.1038~1043 (2001)[DOI]
- Bolte MA, "Case of fluoxetine-induced remission of Raynaud's phenomenon--a case report", Angiology, 44, pp.161~163 (1993)[DOI]
- Skop BP, "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors", Psychosomatics, 37, pp.12~16 (1996)[DOI]
- Aboul-Fotouh S, "Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats", Can J Physiol Pharmacol, 91, pp.1119~1126 (2013)[DOI]